SCHEMBL5377301

SCHEMBL5377301

CCOC(=O)Cc1ccc(N)c(Oc2cc(Br)cc(C#N)c2)c1F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
EPAS1 Q99814 2/20 0.34
F10 P00742 1/20 0.33
KCNH2 Q12809 2/20 0.32
MAPT P10636 2/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TP53 P04637 1/20 0.32
PGR P06401 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
PKM P14618 1/20 0.31
PDCD1 Q15116 1/20 0.31
CD274 Q9NZQ7 1/20 0.31
CHEK1 O14757 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12132016 0.90 CYP3A4 (0.45) CYP3A4CYP2C9CYP2C19EPAS1F10
SCHEMBL1343942 0.88 CYP3A4 (0.47) CYP3A4CYP2C9CYP2C19EPAS1F10
SCHEMBL13661696 0.88 CYP3A4 (0.50) CYP3A4CYP2C9CYP2C19EPAS1F10
SCHEMBL5372331 0.85 MAPT (0.35) CYP3A4CYP2C9CYP2C19EPAS1MAPT
SCHEMBL2342519 0.85 CYP3A4 (0.34) CYP3A4F10MAPTALDH1A1TP53
SCHEMBL1344213 0.85 CYP3A4 (0.39) CYP3A4CYP2C9CYP2C19EPAS1F10
SCHEMBL1343934 0.83 CYP3A4 (0.41) CYP3A4CYP2C9CYP2C19EPAS1F10
SCHEMBL1344605 0.82 CYP3A4 (0.48) CYP3A4CYP2C9CYP2C19EPAS1F10
SCHEMBL1342509 0.81 CYP3A4 (0.51) CYP3A4CYP2C9CYP2C19EPAS1F10
SCHEMBL1342245 0.80 CYP3A4 (0.48) CYP3A4CYP2C9CYP2C19EPAS1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189718-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2007-03-13 US disclosed
EP-1608629-A1 BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-28 EP disclosed
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2004-10-07 US disclosed
WO-2004085406-A1 BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198736-A1 Non-nucleoside reverse transcriptase inhibitors POLR1A, POLR2A, POLR2E CYP3A4 264/4885CYP2C9 808/4885CYP2C19 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.